José Trigo

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy

Jan B. Vermorken, José Trigo, Ricardo Hitt et al. · Journal of Clinical Oncology · 2007 · 1K citations · Full text

Medicine, Oncology, Pharmacology +16

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Keunchil Park, Eric B. Haura, Natasha B. Leighl et al. · Journal of Clinical Oncology · 2021 · 632 citations · Full text

Medicine, Oncology, Pharmacology +17

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

Charles Butts, Mark A. Socinski, Paul Mitchell et al. · The Lancet Oncology · 2013 · 526 citations · Full text

Medicine, Oncology, Pharmacology +13

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck

José Baselga, José Trigo, Jean Bourhis et al. · Journal of Clinical Oncology · 2005 · 491 citations

Medicine, Oncology, Chemotherapy +13

A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding

Miguel Navarro, Belén Ferrer, José Trigo et al. · Journal of Neuroscience · 2002 · 487 citations · Full text

Medicine, Neuroscience, Pharmacology +16